23/07/2026
Multi-Cancer Blood Tests: Are We Witnessing the Future of Cancer Screening—or Opening Pandora’s Box?
The field of multi-cancer early detection (MCED) is advancing at an unprecedented pace. Blood-based assays such as SPOT-MAS, Galleri, CancerSEEK, and several emerging liquid biopsy platforms promise to detect multiple cancers from a single blood sample by analysing circulating tumour DNA (ctDNA), methylation patterns, and other genomic signatures.
The concept is undeniably exciting. A simple blood test capable of identifying cancers before symptoms develop could transform preventive medicine, particularly for cancers such as ovarian, pancreatic, liver, and gastric cancers, where effective population screening remains elusive.
But as clinicians, our responsibility is to look beyond the technology and ask a more important question:
Can these tests truly function as effective screening tools?
Current data demonstrate encouraging analytical performance, with high specificity and improving positive predictive values. However, sensitivity—especially for Stage I disease, where screening has the greatest impact—remains variable. More importantly, we still lack definitive evidence that these tests reduce cancer-specific mortality or overall mortality in the general population.
A positive blood test is also not a diagnosis.
It often initiates a cascade of investigations:
• CT or MRI scans
• PET-CT imaging
• Endoscopy or colonoscopy
• Targeted ultrasound
• Biopsies and specialist referrals
While this pathway may lead to life-saving early diagnoses in some individuals, it also carries the potential for false positives, incidental findings, increased healthcare costs, patient anxiety, and even unnecessary invasive procedures.
Potential Advantages
✅ One blood test screening for multiple cancers
✅ Non-invasive and likely to improve patient acceptance
✅ May identify cancers without established screening programmes
✅ Potential to detect disease before symptoms appear
✅ Rapid advances in AI and genomic technologies continue to improve performance
Current Challenges
⚠️ Limited sensitivity for some early-stage cancers
⚠️ Positive results require extensive downstream investigations
⚠️ Potential for overdiagnosis and incidental findings
⚠️ Significant economic implications for healthcare systems
⚠️ No conclusive evidence yet that widespread MCED screening reduces mortality
As healthcare professionals, we should embrace innovation—but with scientific rigour. A technically impressive diagnostic test is not automatically an effective population screening programme. History has repeatedly reminded us that early detection only has value if it ultimately improves meaningful patient outcomes.
Perhaps the greatest challenge is ensuring that these tests empower patients rather than frighten them. A screening programme should reduce the burden of disease—not inadvertently create a new burden of uncertainty, anxiety, and unnecessary investigations.
The future of genomic screening is undoubtedly promising, but until robust outcome data become available, these tests are best viewed as adjuncts to established evidence-based screening programmes, rather than replacements.
The real question is no longer “Can we detect cancer?” but “Can we detect it in a way that genuinely improves lives?”
’sHealth
